Rhythm CTO exercises options, sells 5,079 shares
RHYTHM PHARMACEUTICALS, INC. executive Joseph Shulman, Chief Technical Officer, exercised 2,024 stock options at an exercise price of $6.80 per share into common stock on 2026-08-13 and sold 5,079 common shares at $119.75 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
RHYTHM PHARMACEUTICALS, INC. executive Joseph Shulman, Chief Technical Officer, exercised 2,024 stock options at an exercise price of $6.80 per share into common stock on 2026-08-13 and sold 5,079 common shares at $119.75 per share. The options, granted on 2022-02-09 and vesting in 16 installments, now show 5,945 options reported as remaining. These transactions were effected under a Rule 10b5-1 trading plan adopted on 2025-12-15.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Shulman Joseph
Role
Chief Technical Officer
Sold
5,079 shs ($608K)
Approx. gross sale proceeds
$608K
Approx. exercise cost
$14K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) F1, F2 | 2,024 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,024 | $6.80 | $14K |
| Sale | Common Stock F1 | 5,079 | $119.75 | $608K |
Holdings After Transaction:
Stock Options (Right to Buy) — 5,945 contracts (Direct);
Common Stock — 15,915 shares (Direct)
Footnotes (2)
- F1. The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
- F2. The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Key Figures
Options Exercised: 2,024 shares
Exercise Price: $6.80 per share
Shares Sold: 5,079 shares
+4 more
7 metrics
Options Exercised
2,024 shares
Stock options exercised into common stock on 2026-08-13
Exercise Price
$6.80 per share
Exercise price of stock options exercised on 2026-08-13
Shares Sold
5,079 shares
Common stock sale on 2026-08-13
Sale Price
$119.75 per share
Per-share price for common stock sold on 2026-08-13
Options Remaining
5,945 options
Stock options reported as held following the option exercise
Option Expiration
2032-02-08
Expiration date of the stock options exercised
10b5-1 Plan Adoption Date
2025-12-15
Date Shulman adopted Rule 10b5-1 trading plan covering these trades
Key Terms
Rule 10b5-1 trading plan, stock options, derivative security, exercise price
4 terms
Rule 10b5-1 trading plan financial
"were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"The stock options were granted on February 9, 2022."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price: "6.8000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did RYTM’s Chief Technical Officer report in this Form 4?
RHYTHM PHARMACEUTICALS (RYTM) CTO Joseph Shulman reported exercising 2,024 stock options at $6.80 per share and selling 5,079 common shares at $119.75 per share on 2026-08-13, as part of an options exercise and share sale sequence.
How many RYTM stock options did Joseph Shulman exercise and at what price?
Joseph Shulman exercised 2,024 stock options in RHYTHM PHARMACEUTICALS (RYTM) at an exercise price of $6.80 per share. These options converted into an equal number of common shares as part of a derivative exercise transaction reported on 2026-08-13.
Were Joseph Shulman’s RYTM transactions under a Rule 10b5-1 trading plan?
Yes. The Form 4 states the exercise and sale were effected pursuant to a Rule 10b5-1 trading plan for RHYTHM PHARMACEUTICALS (RYTM), which Shulman adopted on 2025-12-15, indicating the trades followed a pre-established trading arrangement.
What RYTM options holdings remain for Joseph Shulman after the reported exercise?
After exercising 2,024 stock options, Shulman is reported as holding 5,945 stock options in RHYTHM PHARMACEUTICALS (RYTM). These options relate to a grant dated 2022-02-09, with vesting in 16 substantially equal installments tied to successive service.
When were Joseph Shulman’s RYTM stock options granted and when do they expire?
The RHYTHM PHARMACEUTICALS (RYTM) stock options were granted to Shulman on 2022-02-09 and expire on 2032-02-08. They vest and become exercisable in 16 substantially equal installments based on continued three-month service intervals following the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
